Mirati Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mirati Therapeutics, Inc.
Bristol Myers Squibb won US FDA approval for Augtyro (repotrectinib), from its $4.1bn Turning Point acquisition last year, in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
M&A activity in 2023 began with March’s $43bn mega-deal for Seagen, but only one eight-figure takeout has occurred since. Still, the values are higher overall than seen in 2022 and might indicate a gradual return to larger deals.
The European Medicines Agency has recommended the conditional approval of Mirati’s lung cancer drug Krazati following a re-examination of its initial negative opinion.
Three orphan drugs were among the eight products recommended for pan-EU marketing approval by the European Medicines Agency this week, while Novartis withdrew its filing for Vijoice.
- Other Names / Subsidiaries
- MethylGene Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.